Psychcast: CME Lessons
By MBL Communications
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Podcast Description
CME-accredited PsychCasts™ are designed to enable physicians to learn about topics related to the fields of psychiatry, neuropsychiatry, and primary care. These PsychCast™ activities have been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. To receive credit for these activities: Download the PsychCast™ and review the related PDF, listen to the PsychCast™, and complete the online CME Posttest/Evaluation (or submit the downloadable CME Posttest/Evaluation by mail or fax). To obtain credit, you should score 70% or better. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate. If you have any questions, please e-mail cme@mblcommunications.com. MBL Communications, Inc., is the independent publisher of the monthly journals Primary Psychiatry and CNS Spectrums. MBL also publishes Psychiatry Weekly, the first clinical wallboard service in the nation covering the psychiatric field. Since 1993, MBL has had a global commitment to advancing CNS science, clinical practice, and evidence-based medicine. For more information, visit mblcommunications.com.
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
| 1 | Posttest & Slides - Medical Comorbidity and Recovery in Individuals with Bipolar Disorder | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 5/1/10 | Free | View In iTunes |
|
2 |
Medical Comorbidity and Recovery in Individuals with Bipolar Disorder | Faculty: Martha Sajatovic, MD | 5/1/10 | Free | View In iTunes |
| 3 | Posttest & Slides - Preventation of Mania and Maintenance Treatment in Bipolar Disorder | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 5/1/10 | Free | View In iTunes |
|
4 |
Preventation of Mania and Maintenance Treatment in Bipolar Disorder | Faculty: Charles L. Bowden, MD | 5/1/10 | Free | View In iTunes |
| 5 | Posttest & Slides - Treatment Guidelines for Acute Manic and Mixed Episodes of Bipolar Disorder | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 5/1/10 | Free | View In iTunes |
|
6 |
Treatment Guidelines for Acute Manic and Mixed Episodes of Bipolar Disorder | Faculty: Mark A. Frye, MD | 5/1/10 | Free | View In iTunes |
| 7 | Posttest & Slides - Overall Diagnostic Assessment of Mixed Episodes in Bipolar Disorder | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 5/1/10 | Free | View In iTunes |
|
8 |
Overall Diagnostic Assessment of Mixed Episodes in Bipolar Disorder | Faculty: Joseph F. Goldberg, MD | 5/1/10 | Free | View In iTunes |
| 9 | Posttest & Slides - Major Depressive Disorder: Collaborative Care: Evidence-Based Models That Improve Primary Care Depressive O | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 4/30/10 | Free | View In iTunes |
|
10 |
Major Depressive Disorder: Collaborative Care: Evidence-Based Models That Improve Primary Care Depressive Outcomes | Faculty: Wayne J. Katon, MD | 4/30/10 | Free | View In iTunes |
| 11 | Posttest & Slides - Major Depressive Disorder: Adherence to Antidepressant Medication: Patient-Centered Shared Decision Making | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 4/30/10 | Free | View In iTunes |
|
12 |
Major Depressive Disorder: Adherence to Antidepressant Medication: Patient-Centered Shared Decision Making Communication to Imp | Faculty: Steven R. Hahn, MD | 4/30/10 | Free | View In iTunes |
| 13 | Posttest & Slides - Major Depressive Disorder: The Role of Residual Symptoms in Nonadherence to Treatment | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 4/30/10 | Free | View In iTunes |
|
14 |
Major Depressive Disorder: The Role of Residual Symptoms in Nonadherence to Treatment | Faculty: Richard C. Shelton, MD | 4/30/10 | Free | View In iTunes |
| 15 | Posttest & Slides - Advances in the Management of Fibromyalgia | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 2/19/10 | Free | View In iTunes |
|
16 |
Advances in the Management of Fibromyalgia | Faculty: Lesley M. Arnold, MD | 2/19/10 | Free | View In iTunes |
| 17 | Posttest & Slides - Fibromyalgia Syndrome: Diagnosis and Comorbidities | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 2/19/10 | Free | View In iTunes |
|
18 |
Fibromyalgia Syndrome: Diagnosis and Comorbidities | Faculty: Benjamin H. Natelson, MD | 2/19/10 | Free | View In iTunes |
| 19 | Posttest & Slides - Fibromyalgia Syndrome: Case-Based Learning | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 2/19/10 | Free | View In iTunes |
|
20 |
Fibromyalgia Syndrome: Case-Based Learning | Faculty: I. Jon Russell, MD, PhD | 2/19/10 | Free | View In iTunes |
| 21 | Posttest & Slides - Differential Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Treatment Options and Comorbidity | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 8/31/09 | Free | View In iTunes |
|
22 |
Differential Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Treatment Options and Comorbidity Considerations | Faculty: David Goodman, MD, Roger McIntyre, MD, FRCPC, and Oscar Bukstein, MD, MPH | 8/31/09 | Free | View In iTunes |
| 23 | Posttest & Slides - Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 6/3/09 | Free | View In iTunes |
|
24 |
Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder | Faculty: Andrew Nierenberg, MD, Sidney Kennedy, MD, FRCPC, R. Bruce Lydiard, PhD, MD, Mark Hyman Rapaport, MD | 6/3/09 | Free | View In iTunes |
| 25 | Posttest & Slides - New Perspectives in the Diagnosis and Management of Insomnia | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 1/27/09 | Free | View In iTunes |
|
26 |
New Perspectives in the Diagnosis and Management of Insomnia | Faculty: David Neubauer, MD, Milton K. Erman, MD, and Phyllis Zee, MD, PhD | 1/27/09 | Free | View In iTunes |
| 27 | Posttest & Slides - Advances in Neuroimaging and Biomarkers | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 12/19/08 | Free | View In iTunes |
|
28 |
Selections from the Alzheimer's Disease Summit: Advances in Neuroimaging and Biomarkers | Faculty: Liana Apostolova, MD, Mark A. Mintun, MD, and Elaine Peskind, MD | 12/19/08 | Free | View In iTunes |
| 29 | Posttest & Slides - Advances in Clinical Assessment | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 12/19/08 | Free | View In iTunes |
|
30 |
Selections from the Alzheimer's Disease Summit: Advances in Clinical Assessment | Ziad Nasreddine, MD Kathleen Welsh-Bohmer, PhD Ellen Woo, PhD | 12/19/08 | Free | View In iTunes |
| 31 | Posttest & Slides - Best Practices in Adult ADHD: Special Considerations | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 11/19/08 | Free | View In iTunes |
|
32 |
Best Practices in Adult ADHD: Special Considerations | Faculty: Lenard A. Adler, MD, Thomas J. Spencer, MD, Mark A. Stein, PhD, and Jeffrey H. Newcorn, MD | 11/19/08 | Free | View In iTunes |
| 33 | Posttest & Slides - Best Practices in Adult ADHD: Neurobiology, Pharmacology, and Emerging Treatments | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 10/30/08 | Free | View In iTunes |
|
34 |
Best Practices in Adult ADHD: Neurobiology, Pharmacology, and Emerging Treatments | Faculty: Lenard A. Adler, MD, Thomas J. Spencer, MD, Mark A. Stein, PhD, and Jeffrey H. Newcorn, MD | 10/30/08 | Free | View In iTunes |
| 35 | Posttest & Slides - Best Practices in Adult ADHD: Epidemiology, Impairments, and Differential Diagnosis | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 9/18/08 | Free | View In iTunes |
|
36 |
Best Practices in Adult ADHD: Epidemiology, Impairments, and Differential Diagnosis | Faculty: Lenard A. Adler, MD, Thomas J. Spencer, MD, Mark A. Stein, PhD, and Jeffrey H. Newcorn, MD | 9/18/08 | Free | View In iTunes |
| 37 | Posttest & Slides - Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression | View the slides discussed in this activity and submit the Posttest and Evaluation to receive free CME credit for this CME PsychCast | 7/14/08 | Free | View In iTunes |
|
38 |
Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression | Faculty: Timothy E. Wilens, MD, Andrew A. Nierenberg, MD, Anthony L. Rostain, MD, and Thomas J. Spencer, MD | 7/14/08 | Free | View In iTunes |
| 39 | Posttest-The Significance, Assessment, and Management of Nonrestorative Sleep in Fibromyalgia Syndrome | -- | 5/20/08 | Free | View In iTunes |
|
40 |
The Significance, Assessment, and Management of Nonrestorative Sleep in Fibromyalgia Syndrome | People with fibromyalgia syndrome (FMS) experience unrefreshing sleep, aches, hypersensitivity, and cognitive and emotional difficulties. Although no specific causative factor or biological agent is known to account for all of the features of FMS and these related diagnoses, the generalized hypersensitivity of the body is considered to be affected by disturbances in central nervous system (CNS) functions. Such CNS disturbances are intrinsic to the sleeping-waking brain, where the common symptom elements in all these illnesses are poor quality of sleep, nonspecific pain, fatigue, and psychological distress in the absence of known disease pathology. | 5/20/08 | Free | View In iTunes |
| 41 | Posttest-Fibromyalgia Syndrome: Approach to Management | -- | 5/20/08 | Free | View In iTunes |
|
42 |
Fibromyalgia Syndrome: Approach to Management | The management of fibromyalgia syndrome (FMS) has traditionally been multimodal and multidisciplinary, including education, physical modalities, and medication. In this article, an acronym is offered to help the clinician remember the important components of management. An improved understanding of the pathogenesis of FMS has allowed substantial refinements in its treatment. This is particularly true for medications that target specific symptom domains, allowing individualization of therapy. Since all FMS patients experience pain, there has been emphasis on that domain although medications are now available to address two or more domains with monotherapy. In addition, a logical basis is provided to help the clinician design strategic polypharmacy. | 5/20/08 | Free | View In iTunes |
| 43 | Posttest-Social Influences on the Concept of Fibromyalgia | -- | 5/20/08 | Free | View In iTunes |
|
44 |
Social Influences on the Concept of Fibromyalgia | Despite relevant evidence of physical illness promoting fibromyalgia syndrome (FMS), some authors claim that it is a psychological illness, or due to “psychological amplification.” Good evidence for such views is lacking. Selection processes lead to increased rates of psychological illness in general practice and in specialist practice. The physical distress of FMS can increase both anxiety and depression. Questionable research supported by the insurance industry has tended to provide negative and disparaging views of pain. Current imaging studies support the view that central effects connected with FMS relate to the processing of noxious stimulation more than affective disorder. | 5/20/08 | Free | View In iTunes |
| 45 | Posttest-Fibromyalgia Syndrome: Presentation, Diagnosis, Differential Diagnosis, and Vulnerability | -- | 5/20/08 | Free | View In iTunes |
|
46 |
Fibromyalgia Syndrome: Presentation, Diagnosis, Differential Diagnosis, and Vulnerability | Fibromyalgia syndrome (FMS) presents with widespread soft tissue pain. Common comorbidities include severe insomnia, body stiffness, affective symptoms, irritable bowels, and urethral syndrome. A 1990 research classification depends on a history of widespread pain and prominent tenderness to palpation at 11 or more of 18 specific tender points. It is a criteria-based diagnosis rather than one by exclusion and can accompany other medical conditions. FMS occurs worldwide, and can present any age, but is most common in adult females. Although numerous studies and reviews contend that FMS may be caused by psychological stress such as sexual abuse, critical epidemiological review fails to support that concept. Existing data suggest that some individuals with FMS may have a dysregulated physiological stress response system that predates the onset of symptoms. | 5/20/08 | Free | View In iTunes |
| 47 | Posttest-Psychophysical and Neurochemical Abnormalities of Pain Processing in Fibromyalgia | -- | 5/20/08 | Free | View In iTunes |
|
48 |
Psychophysical and Neurochemical Abnormalities of Pain Processing in Fibromyalgia | Fibromyalgia pain is frequent in the general population, but its pathogenesis is only partially understood. Patients with fibromyalgia lack consistent tissue abnormalities but display features of hyperalgesia (increased sensitivity to painful stimuli) and allodynia (lowered pain threshold). Many recent fibromyalgia studies have demonstrated central nervous system (CNS) pain processing abnormalities, including abnormal temporal summation of pain. In the CNS, persistent nociceptive input from peripheral tissues can lead to neuroplastic changes resulting in central sensitization and pain. This mechanism appears to represent a hallmark of fibromyalgia and many other chronic pain syndromes, including irritable bowel syndrome, temporomandibular disorder, migraine, and low back pain. Importantly, after central sensitization has been established, only minimal peripheral input is required for the maintenance of the chronic pain state. Additional factors, including pain-related negative affect and poor sleep have been shown to significantly contribute to clinical fibromyalgia pain. Better understanding of these mechanisms and their relationship to central sensitization and clinical pain will provide new approaches for the prevention and treatment of fibromyalgia and other chronic pain syndromes. | 5/20/08 | Free | View In iTunes |
| 49 | Quiz-Update on the Etiology and Treatment of Schizophrenia and Bipolar Disorder | Schizophrenia and bipolar disorder are two debilitating mental health disorders, both of which manifest early in adulthood and are associated with severe impairment as well as increased suicide risk. In addition, factors affecting disease severity, such as substance abuse, are often prevalent in these patient populations. In the United States, the prevalence of bipolar disorder is believed to be ~3.5%, while the rate for schizophrenia is ~1%. Although each disorder presents with its own symptom profile, the approaches to treatment are similar and include early diagnosis and use of psychosocial therapy. Research initiatives, such as genetic studies, are used in both disorders as well. For schizophrenia, treatment typically includes the combination of an antipsychotic and psychosocial intervention. For bipolar disorder, clinicians commonly prescribe mood-stabilizing drugs (eg, lithium, valproic acid) as first-line treatment. Many of the second-generation antipsychotics have been approved by the US Food and Drug Administration for bipolar disorder treatment in the manic phase. Patients who are affected by either disorder also face the challenges of treatment nonadherence, which can be affected by substance abuse and can hinder symptom remission as well as spur unnecessary medication switches due to nonresponse. Family members play a key role in the treatment of either disorder. This expert review supplement focuses on treatment options and research strategies being utilized for the management and advanced understanding of schizophrenia and bipolar disorder. Research examining the pharmacology of commonly used medications for the treatment of both disorders is also presented. | 3/31/08 | Free | View In iTunes |
|
50 |
Update on the Etiology and Treatment of Schizophrenia and Bipolar Disorder | Schizophrenia and bipolar disorder are two debilitating mental health disorders, both of which manifest early in adulthood and are associated with severe impairment as well as increased suicide risk. In addition, factors affecting disease severity, such as substance abuse, are often prevalent in these patient populations. In the United States, the prevalence of bipolar disorder is believed to be ~3.5%, while the rate for schizophrenia is ~1%. Although each disorder presents with its own symptom profile, the approaches to treatment are similar and include early diagnosis and use of psychosocial therapy. Research initiatives, such as genetic studies, are used in both disorders as well. For schizophrenia, treatment typically includes the combination of an antipsychotic and psychosocial intervention. For bipolar disorder, clinicians commonly prescribe mood-stabilizing drugs (eg, lithium, valproic acid) as first-line treatment. Many of the second-generation antipsychotics have been approved by the US Food and Drug Administration for bipolar disorder treatment in the manic phase. Patients who are affected by either disorder also face the challenges of treatment nonadherence, which can be affected by substance abuse and can hinder symptom remission as well as spur unnecessary medication switches due to nonresponse. Family members play a key role in the treatment of either disorder. This expert review supplement focuses on treatment options and research strategies being utilized for the management and advanced understanding of schizophrenia and bipolar disorder. Research examining the pharmacology of commonly used medications for the treatment of both disorders is also presented. | 3/31/08 | Free | View In iTunes |
| 51 | Quiz-Neuroprotection: A New Strategy in the Treatment of Schizophrenia | Intervention in the progression of schizophrenia is an effort not just to deter psychosis but also to protect the brain from physiologic deterioration. Neurodegeneration is believed to result from neurochemical dysregulation during the onset of schizophrenia. Deterioration accrued over recurring psychotic episodes causes cumulative loss of cell processes, loss of gray matter volume, and apoptosis. Neurodegeneration ultimately results in persistent symptomology and functional impairment. Functional decline occurs early in the course of schizophrenia, and the symptoms that emerge during the prodromal stage may derail the normal adolescent neurodevelopment. Both first-episode psychosis and the prodrome may be opportunities to forestall neurodegeneration. Unfortunately, people with schizophrenia often experience a long duration of untreated psychosis. Treatment of first-episode psychosis with antipsychotic agents shows robust response. However, early-stage patients have very high rates of medication noncompliance. Treatment in the prodrome may offer the best chance to delay the onset of illness, perhaps mitigate its severity after onset, or even prevent onset entirely. Nonpharmacologic treatments during the prodrome, such as education, treatment for substance use, and cognitive-behavioral therapy, are low-risk interventions that are potentially beneficial. Pharmacologic interventions during the prodrome are also effective in delaying onset of illness, but carry the risk of adversely affecting patients who are false positives for prodromal schizophrenia. In this Expert Roundtable PsychCast™, Jeffrey A. Lieberman, MD, provides an overview of the neurobiological basis of neurodegeneration and the concept of neuroprotection. Next, Peter Buckley, MD, reviews the importance of first-episode psychosis, including duration of untreated illness and medication adherence. Finally, Diana O. Perkins, MD, reviews treatment strategies of prodromal schizophrenia. | 11/19/07 | Free | View In iTunes |
|
52 |
Neuroprotection: A New Strategy in the Treatment of Schizophrenia | Intervention in the progression of schizophrenia is an effort not just to deter psychosis but also to protect the brain from physiologic deterioration. Neurodegeneration is believed to result from neurochemical dysregulation during the onset of schizophrenia. Deterioration accrued over recurring psychotic episodes causes cumulative loss of cell processes, loss of gray matter volume, and apoptosis. Neurodegeneration ultimately results in persistent symptomology and functional impairment. Functional decline occurs early in the course of schizophrenia, and the symptoms that emerge during the prodromal stage may derail the normal adolescent neurodevelopment. Both first-episode psychosis and the prodrome may be opportunities to forestall neurodegeneration. Unfortunately, people with schizophrenia often experience a long duration of untreated psychosis. Treatment of first-episode psychosis with antipsychotic agents shows robust response. However, early-stage patients have very high rates of medication noncompliance. Treatment in the prodrome may offer the best chance to delay the onset of illness, perhaps mitigate its severity after onset, or even prevent onset entirely. Nonpharmacologic treatments during the prodrome, such as education, treatment for substance use, and cognitive-behavioral therapy, are low-risk interventions that are potentially beneficial. Pharmacologic interventions during the prodrome are also effective in delaying onset of illness, but carry the risk of adversely affecting patients who are false positives for prodromal schizophrenia. In this Expert Roundtable PsychCast™, Jeffrey A. Lieberman, MD, provides an overview of the neurobiological basis of neurodegeneration and the concept of neuroprotection. Next, Peter Buckley, MD, reviews the importance of first-episode psychosis, including duration of untreated illness and medication adherence. Finally, Diana O. Perkins, MD, reviews treatment strategies of prodromal schizophrenia. | 11/14/07 | Free | View In iTunes |
| Total: 52 Episodes |
Listeners also subscribed to
- Psychcast: Expert Interviews
- MBL Communications
- View In iTunes
- Psychcast: Expert Roundtable Sessions
- MBL Communications
- View In iTunes
- Sages of Psychopharmacology Podcast
- Neuroscience Education Institute
- View In iTunes
- MGH Psychiatry Academy
- MGH Psychiatry Academy
- View In iTunes
